Hashimoto et al. retrospectively investigated the prognostic significance of 18F-FDG uptake as a predictive marker before treatment with anti-PD-1 antibody in 85 patients with previously treated NSCLC [39]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.